All of Us Research Program
Do you want to change the future of health? The Froedtert & MCW health network is part of the National Institutes of Health All of Us Research Program. It has a simple mission — speed up health research breakthroughs. To do this, All of Us is asking one million people to share their health information. Learn how you can help make a difference by joining the All of Us Research Program.
A Phase 0 Trial of HB-201 for Subjects with Transoral Resectable Human Papillomavirus 16 Positive (HPV 16+) Oropharynx Cancer or with Locally Advanced Cervical Cancer Treated with Chemotherapy and Radiation
profiles in subjects with HPV 16+ head and neck cancer (HNC) and cervical cancer. To compare the immunologic response of HB-201 when it is administered as an IV or IT injection.
Phase I, First In Human Trial Evaluating BI 1387446 Alone And In Combination with BI 754091 in Solid Tumors
A Phase I Study of MR-Guided Dose-Escalated Hypofractionated Adaptive Radiation Therapy and Immunotherapy in Primary Metastatic or Very Locally Advanced Patients with Head and Neck Cancer
A Pivotal Trial Of Envafolimab, And Envafolimab In Combination With Ipilimumab, In Patients With Advanced Or Metastatic Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma Who Have Progressed On Prior Chemotherapy
Tumor-Agnostic Precision Immunooncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial PLATFORM TRIAL
using somatic alterations and potential predictive biomarkers identified via NGS assays
in patients with solid tumors.
A Phase 1, Multicenter, Open-label, Multiple-ascending Dose Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of KPG-818 in Subjects with Hematological Malignancies
Phase 1 Multicenter, Open-Label, Dose Escalation Study and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of STP705 Administered Intratumorally in Cholangiocarcinoma, Hepatocellular Carcinoma or Liver Metastases in Subjects With Advanced / Metastatic or Surgically Unresectable Solid Tumors Who Are Refractory to Standard Therapy
Phase 2, Randomized, Open-Label Three-Arm Clinical Study To Evaluate The Safety And Efficacy Of Lenvatinib (E7080/MK-7902) In Combination With Pembrolizumab (MK-3475) Versus Standard Of Care Chemotherapy And Lenvatinib Monotherapy In Participants With Recurrent/Metastatic Head And Neck Squamous Cell Carcinoma (R/M HNSCC) That Have Progressed After Platinum Therapy And Immunotherapy (PD-1/PD-L1 Inhibitors) (LEAP-009)
KEYSTROKE: A Randomized Phase II Study of Pembrolizumab (KEYTRUDA) Plus Stereotactic Re-Irradiation Versus SBRT Alone for Locoregionally Recurrent or Second Primary Head and Neck Cancer
Randomized Phase II/III trial of adjuvant radiation therapy with Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in pathologic high-risk Squamous Cell Cancer of the head and neck
Transdermal buprenorphine for the treatment of radiation induced mucositis pain in head & neck cancer patients: A pilot study
A Phase 1b Study of Subcutaneous Daratumumab Regimens in Combination with Bispecific T Cell Redirection Antibodies for the Treatment of Subjects with Multiple Myeloma
An Open-Label, Phase 1 Study Of KHK2455 In Combination With Avelumab In Adult Subjects With Locally Advanced Or Metastatic Urothelial Carcinoma
1. Test and study the side effects (to determine the safety) of KHK2455 when taken in combination with avelumab; and
2. Identify the highest dose of KHK2455 that can be given and safely tolerated in combination with avelumab.